Prostate cancer trials in Japan

In Japan 43 Also abroad 1481

43 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Kashiwa
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 3Taking people
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Where
Chiba, Chuo Ku, Fukuoka, Fukushima, Hiroshima, Kamakura, Kobe, Kumamoto, Kyoto, Nagoya, Sapporo, Yokohama
Age
18 years to 100 years
People
940 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06855277
Phase 1/2Taking people
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Where
Fukuoka, Sapporo
Age
18 years and over
People
123 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07226986 · EU 2025-521859-23-00
Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Chiba, Fukuoka, Hiroshima, Kamakura-shi, Kawagoe-shi, Kisarazu-shi, Kita-gun, Kobe, Kumamoto, Maebashi, Nagano, Nagasaki, Nagoya, Osaka, Sakai, Sakura-shi, Sapporo, Suita-shi, Yokohama
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Bunkyō City, Fukuoka, Kamakura-shi, Kawagoe-shi, Kawasaki-shi, Kisarazu-shi, Kumamoto, Kyoto, Maebashi, Miyazaki, Ōta-ku, Sagamihara-shi, Shimotsuke-shi, Yokohama
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Chiba, Fukuoka, Kanazawa, Kobe, Kumamoto, Matsuyama, Osaka, Sapporo, Shinjuku-ku, Suita, Yamagata, Yokohama, Yokosuka
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Where
Kanagawa, Tokyo
Age
18 years and over
People
85 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06990880 · EU 2025-521581-10-00
Phase 3Taking people
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
Where
Tokyo, Tottori
Age
18 years and over
People
684 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07802704 · EU 2026-525558-13-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Chūōku, Kashiwa, Kōtoku, Nagoya, Shinagawa-ku, Suita-shi
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 2/3Taking people
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Where
Chiba, Fukuoka, Fukushima, Ishikawa, Kashiwa, Kobe, Kyoto, Sapporo, Yokohama
Age
18 years to 100 years
People
443 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06780670 · EU 2024-512342-42-00
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Chuo Ku
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Chūōku
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 2Taking people
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Where
Bunkyo-ku, Fukuoka, Kashiwa, Koto, Osaka, Sunto-gun
Age
18 years and over
People
218 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00
Phase 1/2Taking people
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Where
Chūōku, Hirakata-shi, Kashiwa
Age
18 years and over
People
52 worldwide
Run by
AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00
Phase 1Taking people
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Kashiwa-shi, Koto-ku, Yokohama
Age
18 years and over
People
479 worldwide
Run by
Amgen
See details and how to joinNCT04221542 · EU 2023-504361-23-00
Phase 1Taking people
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Koto-ku, Yokohama
Age
18 years and over
People
198 worldwide
Run by
Bayer
See details and how to joinNCT06217822 · EU 2023-507486-26-00
Phase 1/2Taking people
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Where
Chuo Ku, City
Age
18 years and over
People
27 worldwide
Run by
Tanabe Pharma America, Inc.
See details and how to joinNCT06943521
No phaseNot yet taking people in Japan
LTFU for All Cell and Gene Therapy Studies
Where
Kashiwa, Kyoto, Osakasayama-shi
Age
18 years to 130 years
People
64 worldwide
Run by
AstraZeneca
See details and how to joinNCT06194461